Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characteriz...

Source: Allergy, Asthma and Clinical Immunology - January 17, 2019 Category: Allergy & Immunology Authors: Samira Jeimy, Pari Basharat and Fiona Lovegrove Tags: Case report Source Type: research